Guardant Receives FDA Approval for New Diagnostic Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Should l Buy GH?
Source: Newsfilter
- FDA Approval: The Guardant360® CDx has received FDA approval as a companion diagnostic for VEPPANU, marking a significant advancement in precision oncology and is expected to enhance treatment options and outcomes for patients.
- Non-Invasive Testing Advantage: This blood-based test identifies patients with ESR1 mutations, enabling earlier treatment decisions by physicians, which could improve survival rates and quality of life for patients with advanced breast cancer.
- Clinical Data Support: The approval is backed by clinical data demonstrating the utility of identifying ESR1 mutations in ER+/HER2- advanced breast cancer patients, further solidifying the application of Guardant360 CDx across multiple tumor types.
- Expanded Market Coverage: With its 26th companion diagnostic indication covering over 300 million lives, Guardant360 CDx demonstrates broad acceptance in the market and significant commercial potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GH
Wall Street analysts forecast GH stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 95.700
Low
105.00
Averages
124.69
High
155.00
Current: 95.700
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardant Health (GH) Q1 2026 Earnings Transcript
See More
Guardant Health Chief Medical Officer Resigns
- Executive Departure: Guardant Health's Chief Medical Officer Craig Eagle has resigned effective Friday, and while the SEC filing did not disclose reasons or a successor, this change could impact the company's strategic direction and medical decision-making.
- Background Information: Eagle previously served as Vice President of Medical Affairs Oncology at Roche's subsidiary Genentech and held several leadership positions at Pfizer, bringing significant expertise to Guardant Health during his tenure.
- Strategic Advisory Role: Prior to his resignation, Eagle joined OS Therapies' strategic advisory board in April, indicating his ongoing influence in the biotech sector, which may indirectly affect Guardant Health's competitive positioning.
- Financial Performance: Despite the executive change, Guardant Health reported a non-GAAP EPS of -$0.45 for Q1 2026, beating expectations by $0.02, with revenue of $301.7 million exceeding forecasts by $22.64 million, demonstrating strong momentum in the liquid biopsy testing market.
See More
Guardant Health Reports Strong Q1 2026 Earnings with 48% Revenue Growth
- Significant Revenue Growth: Guardant Health achieved $302 million in revenue for Q1 2026, representing a 48% year-over-year increase, marking the fastest annual growth rate in the last five years, indicating strong business momentum and heightened market demand.
- Accelerated Oncology Revenue: Oncology revenue grew by 36%, driving Q1 revenue to $205 million, reflecting the company's ongoing expansion in cancer diagnostics and an enhanced customer base.
- Strong Product Performance: The Reveal product saw over 100% year-over-year growth in its first full quarter, demonstrating strong market acceptance of its new therapy response monitoring use case, further solidifying the company's leadership in the liquid biopsy market.
- Optimistic Financial Outlook: The company raised its full-year 2026 revenue guidance to a range of $1.30 billion to $1.32 billion, expecting growth of 32% to 34%, while projecting Shield testing revenue to reach $186 million to $198 million, showcasing robust momentum for future growth.
See More
Guardant Receives FDA Approval for New Diagnostic Test
- FDA Approval: The Guardant360® CDx has received FDA approval as a companion diagnostic for VEPPANU, marking a significant advancement in precision oncology and is expected to enhance treatment options and outcomes for patients.
- Non-Invasive Testing Advantage: This blood-based test identifies patients with ESR1 mutations, enabling earlier treatment decisions by physicians, which could improve survival rates and quality of life for patients with advanced breast cancer.
- Clinical Data Support: The approval is backed by clinical data demonstrating the utility of identifying ESR1 mutations in ER+/HER2- advanced breast cancer patients, further solidifying the application of Guardant360 CDx across multiple tumor types.
- Expanded Market Coverage: With its 26th companion diagnostic indication covering over 300 million lives, Guardant360 CDx demonstrates broad acceptance in the market and significant commercial potential.
See More
Guardant Health and Nuvalent Forge Long-Term Partnership to Create Companion Diagnostics and Aid in the Commercialization of Targeted Cancer Treatments via the Guardant Infinity™ Platform
Strategic Collaboration Announcement: Guardant Health has announced a multi-year strategic collaboration with Nuvalent to develop companion diagnostics for targeted cancer therapies.
Focus on Cancer Therapies: The partnership aims to enhance the development of diagnostics that support the commercialization of specific cancer therapies.
Utilization of Technology: The collaboration will leverage the Guardant Infinity™ platform to facilitate advancements in cancer diagnostics.
Potential Impact: This initiative is expected to improve patient outcomes by providing tailored diagnostic solutions for targeted cancer treatments.
See More
Verana Health Partners with Guardant Health to Enhance Cancer Therapy Development
- Data Integration Advantage: The partnership between Verana Health and Guardant Health combines high-quality EHR data with genomic data, enabling biopharmaceutical researchers to better understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies and enhancing patient care quality.
- Enhanced Clinical Insights: By integrating NMIBC EHR data with genomic data, researchers can more accurately assess patient risk and optimize treatment choices, particularly regarding the applicability of BCG therapy, which improves treatment efficacy and patient satisfaction.
- Market Coverage Expansion: This collaboration extends Verana Health's cancer care data to solid tumors such as lung, breast, and colorectal cancers, enhancing the diversity of the dataset and clinical insights, allowing it to serve 17 of the top 20 global biopharma companies.
- Regulatory Collaboration Strengthening: The combined regulatory expertise of both companies positions them as a top-tier partner for close collaboration with the FDA, further solidifying Verana Health's standing in the biopharma industry and accelerating the implementation of clinical trial solutions.
See More
Guardant Health (GH) Q1 2026 Earnings Transcript
See More
Guardant Health Chief Medical Officer Resigns
- Executive Departure: Guardant Health's Chief Medical Officer Craig Eagle has resigned effective Friday, and while the SEC filing did not disclose reasons or a successor, this change could impact the company's strategic direction and medical decision-making.
- Background Information: Eagle previously served as Vice President of Medical Affairs Oncology at Roche's subsidiary Genentech and held several leadership positions at Pfizer, bringing significant expertise to Guardant Health during his tenure.
- Strategic Advisory Role: Prior to his resignation, Eagle joined OS Therapies' strategic advisory board in April, indicating his ongoing influence in the biotech sector, which may indirectly affect Guardant Health's competitive positioning.
- Financial Performance: Despite the executive change, Guardant Health reported a non-GAAP EPS of -$0.45 for Q1 2026, beating expectations by $0.02, with revenue of $301.7 million exceeding forecasts by $22.64 million, demonstrating strong momentum in the liquid biopsy testing market.
See More
Guardant Health Reports Strong Q1 2026 Earnings with 48% Revenue Growth
- Significant Revenue Growth: Guardant Health achieved $302 million in revenue for Q1 2026, representing a 48% year-over-year increase, marking the fastest annual growth rate in the last five years, indicating strong business momentum and heightened market demand.
- Accelerated Oncology Revenue: Oncology revenue grew by 36%, driving Q1 revenue to $205 million, reflecting the company's ongoing expansion in cancer diagnostics and an enhanced customer base.
- Strong Product Performance: The Reveal product saw over 100% year-over-year growth in its first full quarter, demonstrating strong market acceptance of its new therapy response monitoring use case, further solidifying the company's leadership in the liquid biopsy market.
- Optimistic Financial Outlook: The company raised its full-year 2026 revenue guidance to a range of $1.30 billion to $1.32 billion, expecting growth of 32% to 34%, while projecting Shield testing revenue to reach $186 million to $198 million, showcasing robust momentum for future growth.
See More
Guardant Receives FDA Approval for New Diagnostic Test
- FDA Approval: The Guardant360® CDx has received FDA approval as a companion diagnostic for VEPPANU, marking a significant advancement in precision oncology and is expected to enhance treatment options and outcomes for patients.
- Non-Invasive Testing Advantage: This blood-based test identifies patients with ESR1 mutations, enabling earlier treatment decisions by physicians, which could improve survival rates and quality of life for patients with advanced breast cancer.
- Clinical Data Support: The approval is backed by clinical data demonstrating the utility of identifying ESR1 mutations in ER+/HER2- advanced breast cancer patients, further solidifying the application of Guardant360 CDx across multiple tumor types.
- Expanded Market Coverage: With its 26th companion diagnostic indication covering over 300 million lives, Guardant360 CDx demonstrates broad acceptance in the market and significant commercial potential.
See More
Guardant Health and Nuvalent Forge Long-Term Partnership to Create Companion Diagnostics and Aid in the Commercialization of Targeted Cancer Treatments via the Guardant Infinity™ Platform
Strategic Collaboration Announcement: Guardant Health has announced a multi-year strategic collaboration with Nuvalent to develop companion diagnostics for targeted cancer therapies.
Focus on Cancer Therapies: The partnership aims to enhance the development of diagnostics that support the commercialization of specific cancer therapies.
Utilization of Technology: The collaboration will leverage the Guardant Infinity™ platform to facilitate advancements in cancer diagnostics.
Potential Impact: This initiative is expected to improve patient outcomes by providing tailored diagnostic solutions for targeted cancer treatments.
See More
Verana Health Partners with Guardant Health to Enhance Cancer Therapy Development
- Data Integration Advantage: The partnership between Verana Health and Guardant Health combines high-quality EHR data with genomic data, enabling biopharmaceutical researchers to better understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies and enhancing patient care quality.
- Enhanced Clinical Insights: By integrating NMIBC EHR data with genomic data, researchers can more accurately assess patient risk and optimize treatment choices, particularly regarding the applicability of BCG therapy, which improves treatment efficacy and patient satisfaction.
- Market Coverage Expansion: This collaboration extends Verana Health's cancer care data to solid tumors such as lung, breast, and colorectal cancers, enhancing the diversity of the dataset and clinical insights, allowing it to serve 17 of the top 20 global biopharma companies.
- Regulatory Collaboration Strengthening: The combined regulatory expertise of both companies positions them as a top-tier partner for close collaboration with the FDA, further solidifying Verana Health's standing in the biopharma industry and accelerating the implementation of clinical trial solutions.
See More
